These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 1057692)
41. Aluminum an uremic toxin. D'Haese PC; Van de Vyver FL; Lamberts LV; De Broe ME Adv Exp Med Biol; 1987; 223():89-96. PubMed ID: 3447454 [No Abstract] [Full Text] [Related]
42. [Determination of "middle molecules" presenting vitamin B12 molecular size in normal and uremic body fluids (author's transl)]. Cueille G J Chromatogr; 1978 Jul; 146(1):55-65. PubMed ID: 670358 [TBL] [Abstract][Full Text] [Related]
43. Biochemical and clinical evidence for uremic toxicity. Bouré T; Vanholder R Artif Organs; 2004 Mar; 28(3):248-53. PubMed ID: 15046622 [TBL] [Abstract][Full Text] [Related]
45. What remains of the "middle molecule" hypothesis today? Brunner H; Mann H Contrib Nephrol; 1985; 44():14-39. PubMed ID: 3886282 [No Abstract] [Full Text] [Related]
46. Extracorporeal strategies for the removal of middle molecules. Winchester JF; Audia PF Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287 [TBL] [Abstract][Full Text] [Related]
47. Recent progress in the analysis of uremic toxins by mass spectrometry. Niwa T J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(25):2600-6. PubMed ID: 19083276 [TBL] [Abstract][Full Text] [Related]
48. New insights in uremic toxins. Vanholder R; Glorieux G; De Smet R; Lameire N; Kidney Int Suppl; 2003 May; (84):S6-10. PubMed ID: 12694297 [TBL] [Abstract][Full Text] [Related]
52. [Isolation, structure elucidation and synthesis of a hexapeptide from the hemodialysate of uremic patients]. Bovermann G; Rautenstrauch H; Seybold G; Jung G Hoppe Seylers Z Physiol Chem; 1982 Oct; 363(10):1187-202. PubMed ID: 7141402 [TBL] [Abstract][Full Text] [Related]
53. Middle molecules as a marker of uremic toxins. Wu ZG; Liao LT; Cai ZH; Lu ZN; Cai YD; Sheng PF Adv Exp Med Biol; 1987; 223():33-7. PubMed ID: 3447449 [No Abstract] [Full Text] [Related]
54. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia]. Trznadel K; Kidawa Z; Walasek L; Lutz W Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030 [No Abstract] [Full Text] [Related]
55. Renal versus continuous versus intermittent therapies for removal of uremic toxins. Clark WR; Henderson LW Kidney Int Suppl; 2001 Feb; 78():S298-303. PubMed ID: 11169030 [TBL] [Abstract][Full Text] [Related]
56. [Determination of substances of middle molecular mass in the body fluids of patients treated with intermittent peritoneal dialysis]. Dukanović L; Petrović J Lijec Vjesn; 1982; 104(11-12):527-9. PubMed ID: 7187480 [No Abstract] [Full Text] [Related]
57. Transport of small, middle, and large molecular weight substances in a dual filtration artificial kidney. Smeby LC; Jörstad S; Wideröe TE; Svartaas TM Artif Organs; 1981; 4 Suppl():104-9. PubMed ID: 7295075 [TBL] [Abstract][Full Text] [Related]
58. Removal of waste metabolites in uremia by microencapsulated reactants. Sparks RE; Salemme RM; Meier PM; Litt MH; Lindan O Trans Am Soc Artif Intern Organs; 1969; 15():353-9. PubMed ID: 5791409 [No Abstract] [Full Text] [Related]
59. [The role of dialysis membranes in elimination of uremic toxins]. Grzeszczak W; Zukowska-Szczechowska E; Rutkowski B Przegl Lek; 1996; 53(5):439-42. PubMed ID: 8754410 [No Abstract] [Full Text] [Related]